ABSTRACT AMP) forming enzyme in mice, the effect of streptozotocin (STZ) on the enzyme activities and adenine nucleotide levels in the ICR mice (4-week-old) liver was examined. After 2 weeks, treatment with a single dosage of STZ (100, 150 or 200 mg/kg i.p.) induced a dose-dependent hyperglycemia and hypoinsulinemia but had no effect on serum alanine aminotransferase activity, indicating that STZ generated type 1 diabetes without hepatitis. In the diabetic liver, the activities of superoxide dismutase (SOD), catalase and ATP levels decreased, and the microsomal CYP2E1 activity increased. Changes of these biological activities might disrupt the cellular homeostatic balance of reactive oxygen species (ROS) production. The activities of 3'-AMP forming enzyme, one of the ribonucleases, in hepatic homogenates were not altered. However, in the STZ 200 mg/kg group, the cytosolic forming enzyme activities were in the mitochondrial activity may be accelerated by development of diabetes due to the decrease in the antioxidant defense system and/or increase in ROS production. With the decrease in the 3'-AMP forming enzyme activity, the levels of 3'-AMP, a P-site inhibitor of adenylate cyclase, in mitochondrial were -ment of diabetes. Our results also suggested that change in cytosolic enzyme activity might serve as a new 3'-AMP forming enzyme and SOD was found in the early stage of diabetes.
INTRODUCTION
Intracellular adenosine 3'-monophosphate (3'-AMP) is pharmacologically recognized as an intracellular Pet al., 1990; Iwatsubo et al., 2006) . The 3'-AMP forming enzyme, one of the ribonucleases (RNases), is known to exist not only et al., 1990; Fujimori et al., 2004) and mice (Fujimori et al., 2001 ) but also in mitochondria of rat liver Fujimori and Pan-Hou, 2002) . However, the pathophysiological roles of 3'-AMP and its forming enzyme have not yet been elucidated. Streptozotocin (STZ) is known to exert toxic effects not including liver (Weiss, 1982; Kume et al., 1994; Haluzík and Nedvídková, 2000; Kume et al., 2004 ) . The liver is a major target of insulin action, and plays an important role in maintaining blood glucose levels (Dhahbi et al., 2003; Parker et al et al. (1990) demonstrated that STZ-induced increase in 3'-AMP levels in rat liver could be largely reversed by insulin treatment. From pathophysiological roles of 3'-AMP forming enzyme in liver. Our interest is to know whether diabetes induced by -ties in the cytosol and mitochondria from mouse liver.
In this study, we examined the effect of STZ on adenine nucleotide levels and the 3'-AMP forming enzyme activity in mouse liver. Here we report that decrease in mitochondrial 3'-AMP forming enzyme activity in STZinduced diabetic mouse liver was associated with the increase in cytosolic 3'-AMP forming enzyme activity, and speculated that change in the mitochondrial 3'-AMP -ical change of mitochondrial functions due to reactive oxygen species (ROS) production. 
MATERIALS AND METHODS

Materials
Animals
All laboratory animals for these experiments were treated according to the Guidelines of the Committee for Ethical Use of Experimental Animals at Setsunan University, Japan. Mice were housed in polycarbonate cages in an animal room air-conditioned at a temperature of 25 ± 2°C and a relative humidity of 55 ± 10% with 15 times ventilation per hr under a 12-hr light and dark cycle, and allowed free access to regular chow diet and tap water throughout the experimental period for 2 weeks. Mice were randomly assigned to treatment groups (5 animals/ group) and acclimated for 7 days.
Treatment of mice with STZ
Mouse blood glucose level was measured before STZ injection. After fasting for 24 hr, STZ (100, 150 or 200 mg/kg body weight), freshly dissolved in 0.05 M sodium citrate buffer (pH4.5), was injected intraperitoneally at around 13:00. Mice in the control group were given vehicle alone. At 2 weeks after STZ-injection, the blood was withdrawn from the abdominal aorta of the mouse under ether anesthesia between 13:00 and 16:00, and the serum was obtained by centrifugation at 1,500 x g for 10 min.
Blood and serum biochemistry
Blood glucose level was measured using Glucose Pilot strips (Aventir Biotech, LLC., CA, USA) covered with a drop of blood obtained by a tail-vain puncture just before ether anesthesia. Serum insulin level and the activity of serum alanine aminotransferase (ALT) were measured using an immunoassay kit (Morinaga Institute of Biological Science, Yokohama, Japan) and a transaminase CIItest Wako, respectively. Serum levels of ketone bodies -ured using a Ketolex kit (Sanwa Kagaku Co., Ltd., Aichi, Japan), based on the method described by Williamson et al et al., 1987) . The levels of ketone bodies were calculated by the sum of the
Preparation of crude mitochondria and microsome from mouse liver
All procedures were performed at 0-4°C. The liver was quickly removed from the mouse and weighed. The liver (1.0 g) was homogenized immediately after removal in 9.0 ml of 20 mM Tris-HCl buffer (pH 7.5) containing 0.25 M sucrose, 1 mM EDTA and 5 mM 2-mercaptoethanol. Part of the homogenate obtained was kept at -40°C until use and used as a homogenate enzyme solution. The residual homogenate was then centrifuged at 600 x g for 15 min. The supernatant was centrifuged twice at 9,000 x g for 15 min to separate mitochondria. The pellet was suspended in the same Tris-HCl buffer described above. The suspension obtained was kept at -40°C until use, and used as a crude mitochondrial enzyme solution. The residual supernatant obtained was further centrifuged twice at 210,000 x g for 40 min. The pellet was suspended in the same Tris-HCl buffer, kept at -80°C, and used as a microsomal enzyme solution. The supernatant obtained was also kept at -40°C and used as a cytosolic enzyme solution. Protein was determined by the method of Bradford using bovine serum albumin as a standard (Bradford, 1976) .
Determination of liver glycogen content
Liver glycogen content was measured according to the method described by Suzuki et al -cation (Suzuki et al., 2001) . Glycogen isolated from frozen liver was hydrolyzed to glucose with amyloglucosidase and measured as glucose equivalent using Glucose A. Miyamoto et al. Vol. 33 No. 2 glucosyl units per g wet weight.
Determination of superoxide dismutase (SOD) and catalase activities SOD activity was measured using a SOD test-Wako according to the method based on the inhibition by SOD of nitroblue tetrazolium reduction due to superoxide (Yamanaka et al., 1979) . The SOD activity is expressed as the inhibition (%).
Catalase activity was measured using the method 2 O 2 was preincubated at 37°C. After the reaction mixture, and the absorbance was monitored for 1 min at 240 nm. The change in absorbance is proportional to the breakdown of H 2 O 2 . The catalase activity is expressed as units/mg protein.
Determination of CYP2E1 activity CYP2E1 activity was assayed by p-nitrophenol (PNP) hydroxylation activity in terms of 4-nitrocatechol formation according to the method described by Koop et al. et al., 1997) . The reacphosphate buffer (pH 6.8) containing 1 mM NADPH, 0.1 -absorbance at 546 nm was measured with a spectrophotometer. The CYP2E1 activity is expressed as nmol/min/ mg protein.
Determination of Adenine Compounds by HPLC
Extraction of adenine compounds in the liver with perchloric acid was carried out according to the method previously described . The acid-soluble compounds were treated with 50% chlo-N 6 -etheno-derivatives of ATP, ADP, 5'-AMP, 3'-AMP, and Ado. The derivatized Ado, 3'-AMP and 5'-AMP were analyzed by a reversed-phase HPLC using a column of Chromatorex ODS , and the derivatized ATP, ADP and 5'-AMP were determined using a column (125 x 4.6 mm i.d.) of Hitachi gel No. 3013-N as an anion exchanger (Fujimori et al., 1991) . The eluate was detected with an HPLC system consisting of an Intelligent HPLC pump (Jasco 880-FP, Japan), an Intelligent -tor (Jasco 829-IT, Japan). The adenine compound levels Determination of 3'-AMP forming enzyme activity according to the procedure described previously (Fujimori et al -sisted of 0.1 M acetate buffer (pH 5.6) containing 20 mM solution. After incubation of the mixture at 37°C for 60 2 in 0.5 M perchloric acid were added to stop the reaction. The enzymic products were derivatized with chloroacetaldehyde, and the derivatized compounds were analyzed using a column of Chromatorex ODS maintained at 45°C. The 3'-AMP forming enzyme activity is estimated by the sum of the activity to produce 3'-AMP and Ado, and is expressed as nmol/60 min/mg protein.
Statistical Analysis
All experimental results are expressed as mean ± S.E. Statistical analysis was carried out by Student's t-test or Dunnett's test (Dunnett, 1964) . p values < 0.05 were conExcel software.
RESULTS
The body weights of the STZ 200 mg/kg group were group as shown in Table 1. In the STZ 200 mg/kg group, relative epididymal fat pad weight was lower comparing with those in the control group (Table 1 ). Blood glucose manner ( Fig. 1-A) , and serum insulin levels were sigketone body levels of the STZ 200 mg/kg group were The hepatic SOD activities in STZ 150 and 200 mg/kg of those in the control group, respectively (Fig. 2-A) . The catalase activity in the STZ 200 mg/kg group was significantly reduced to ca. 27% of control activity (Fig. 2-B) . On the other hand, the hepatic CYP2E1 activity in the 1.3-fold of those in the control group (Fig. 2-C) . However, no significant change in serum ALT activity was observed as shown in Fig. 2-D .
Under these experimental conditions mentioned above, the effect of STZ on the levels of adenine compounds Effect of STZ on mouse hepatic 3'-AMP forming enzyme Vol. 33 No. 2 and glycogen in mouse liver was examined. Hepatic glycogen content of the STZ 200 mg/kg group decreased to ca. 56% of the control value ( Table 2 ). As shown in Table  2 , hepatic ATP levels in the STZ 200 mg/kg group was significantly reduced to ca. 56% of control levels. The 5'-AMP levels of STZ 150 and 200 mg/kg groups were --nine compound levels were observed between the control and STZ groups ( Table 2 ). The ratio of 5'-AMP/ATP of the STZ 200 mg/kg group was ca. 3.3-fold higher than that of control. Hepatic 3'-AMP levels of the STZ 200 mg/kg group decreased to ca. 74% of the control levels (Table 2) . On the other hand, hepatic mitochondrial 3'-AMP levels of the STZ 150 and 200 mg/kg groups were levels, respectively (Table 3) .
To study the mechanism of mitochondrial 3'-AMP level reduction, the effect of STZ on 3'-AMP forming enzyme activity in mouse liver was examined. No sigin the crude homogenate were observed as shown in Fig.  3 -A. The 3'-AMP forming enzyme activity in the crude -cantly suppressed to ca. 60% of control values (Fig. 3-B) . On the other hand, the cytosolic activity of the STZ 200 compared with the control value (Fig. 3-C) . In the control group, the mitochondrial 3'-AMP forming enzyme activity was ca. 81-fold higher compared with the cytosolic activity. However, in the STZ 200 mg/kg group, the mitochondrial activity was decreased to ca. 26-fold of the cytosolic one. Next, the 3'-AMP and Ado degrading activities in mouse liver treated with 200 mg/kg STZ were evaluated. As shown in Table 4 , the 3'-AMP degrading activity in mitochondrial fraction was ca. 35 higher than that -ic and mitochondrial 3'-AMP degrading activities were observed when a mouse was treated with 200 mg/kg STZ ( Table 4 ). The Ado degrading activity was only found in cytosolic fraction, in which the activity was not affected by the STZ treatment (Table 4) .
The effect of pCMBS on the 3'-AMP forming enzyme activities in cytosolic and mitochondrial fractions was examined. As shown in Fig. 4 , the treatments with p activities in the cytosolic and mitochondrial fractions.
DISCUSSION
STZ is often used to generate animal models of type cells (Weiss, 1982; Kume et al., 1994; Kume et al., 2004 ) . Under our experimental conditions, a dose-dependent typical hyperglycemia (Fig. 1-A) and hypoinsulinemia ( Fig. 1-B) were observed, indicating that early stages of type 1 diabetes in mice were induced by a single administration of STZ after 2 weeks. During mice housing, proteinuria and glucosuria were detected (data not shown), suggesting that representative nephrotoxicity was elicited by STZ treatment. However, no change in serum ALT activity as shown in Fig. 2 -D strongly indicated that 2 week-STZ treatment did not cause hepatitis with damage to hepatocellular membrane although STZ is known to exert acute hepatic changes including lipid peroxidation, mitochondrial swelling, and inhibition of hepatocyte proliferation before the elevation of the serum glucose levels (Kume et al., 2004) .
STZ-induced hepatic toxicity is thought to be mediated by ROS which produces lipid peroxide in hepatocellular membrane (Ahn et al., 2006; Kayali et al., 2004; Raza et al., 2004) . Cellular homeostatic balance of ROS including superoxide radical might be influenced by 1) CYP2E1 activity which catalyzes the formation of ROS during metabolizing endogenous compounds such as fatty acids, lipid hydroperoxide, and ketone bodies into aldehydes (Tanaka et al., 2000; Mari and Cederbaum., 2001) , 2) ATP-dephosphorylating activity which results in the formation of superoxide radical via supplication of a substrate for xanthine oxidase (Nukatsuka et al., 1988; Nukatsuka et al., 1990) , 3) mitochondrial respiration-linked ROS production (Raza et al., 2004) , 4) antioxidant defensing activity such as SOD and catalase activities (Low et al., 1997) . The increases in CYP 2E1 activity (Fig. 2-C) and serum ketone body levels ( Fig. 1-C) and decreases in hepatic ATP levels (Table  2 ) and the activities of SOD and catalase (Figs. 2-A and B) were observed under our experimental conditions. These biochemical changes may involve an increase of ROS production in the liver after STZ treatment. The increase in the formation of ROS induced by STZ might elicit mitochondrial dysfunction in the mice. Hypertrophy of hepatocytes, which were characterized by a prominent increase in a number of mitochondria (Hamperl, 1962) and a marked decrease in glycogen granules showing normal structure, is known to be induced in diabetic mice 4 to 12 weeks after a single administration of STZ (Kume et al, 1994) . Hepatic hypertrophy (i.e., increase in relative liver weight) was observed in our STZ 200 mg/kg group (Table 1) . However, 2-week-STZ treatments did not induce acute hepatitis because no change in serum ALT activity was observed (Fig. 2-D) . Judging from the large decrease in hepatic ATP levels which are known to be predominantly produced via oxidation phosphorylation in mitochondria, there is no doubt that mitochondrial function was certainly suppressed by STZ (Table 2) . In general, RNase, one of the SH-enzymes, is known to exist as an active form and an inactive form complexed with RNase inhibitor in cells and tissues (Kumagai et al., A. Miyamoto et al. 1991; Deutscher, 1993) . The inactivation of RNase inhibitor, rich in SH residues, by SH reagents such as pCMBS causes the dissociation of the RNase-RNase inhibitor complex into active RNase and inactive inhibitor, in which SH residues are critical for the inhibition of RNase (Ferreras et al., 1995) . RNases do not hydrolyze RNAs to produce Ado directly. Conversion of 3'-AMP to Ado is catalyzed by acid phosphatase , and the yielded Ado is converted to inosine, which is not determined by our HPLC, by Ado deaminase. Therefore, the net 3'-AMP forming enzyme activity is estimated by the sum of the activity to produce 3'-AMP and Ado. Treatment with -ing activity in the liver homogenates but the activity in mitochondrial fraction was largely inhibited (Fig. 3-B) . The forming activity in cytosol was increased along with Effect of STZ on mouse hepatic 3'-AMP forming enzyme the decrease of the forming activity in mitochondrial fraction (Fig. 3) . The increase in cytosolic 3'-AMP forming enzyme activity (Fig. 3-C) may not arise from the activation of the enzyme via inactivation of RNase inhibitor -cant difference in the forming activity both in cytosolic and mitochondrial fractions between the treatment without and with pCMBS (Fig. 4) . In addition, no Ado degrading activity was detected in mitochondrial fraction (Table   activities both in cytosol and mitochondrial fractions was found between with and without STZ treatment. There results clearly suggested that the enhancement of the 3'-AMP forming enzyme activity in the cytosol (Fig. 3-C ) may be at least partly due to the leakage of the enzyme activity from mitochondria probably via ROS-mediated membrane damage.
In this study, we demonstrated that mitochondrial 3'--STZ (Table 3 and Fig. 3-B) . Therefore, much attention should be attracted to elucidate the pathophysiological roles of the mitochondrial 3'-AMP forming enzyme sys-3'-AMP forming enzyme and SOD (r = -0.52, p < 0.05), calculated from the data shown in Figs. 3-C and 2-A, was observed. Therefore, cytosolic 3'-AMP forming enzyme activity in the liver might serve as a biomarker to estimate varying degrees of oxidative stress in the early stage of mouse diabetes. 
